Erlotinib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 109-123

  Steins, M ^a   Thomas, M ^a   Geissler M ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM ESSLINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; INFECTION; LIVER CELL CARCINOMA; LUNG TOXICITY; NON SMALL CELL LUNG CANCER; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STOMATITIS; ANIMAL; DRUG ANTAGONISM; LIVER TUMOR; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PANCREAS CARCINOMA; PANCREAS TUMOR; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906930151     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_6     Document Type: Article

References (73)

1. Alroy I, Yarden Y (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83–86
2. Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 24:3831–3837
3. Birk D, Gansauge F, Gansauge S (1999) Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 25:89–96
4. Boeck S, Hausmann A, Reibke R et al (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109–1111
5. Brabender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850–1855
6. Bramhall SR, Schulz J, Nemunaitis J (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167
7. Buckley AF, Burgart LJ, Sahai V et al (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129:245–251
8. Burris HA 3rd, Moore MJ, Andersen J (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
9. Cappuzzo F, Cileanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised and placebo-controlled phase 3 study. Lancet Oncol 11:521–529
10. Cedrés S, Prat A, Martínez P et al (2009) Clinical surrogate markers of survival in advanced nonsmall cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 66:257–261
11. Chen G, Fen J, Zhou C et al (2013) Quality of life (QoL) analyses from OPTIMAL (CTONG- 0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR-mutation positive non-small cell lung cancer (NSCLC). Ann Oncol 24:1615–1622
12. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
13. Chiang D, Villanueva A, Peix J (2008) Focal VEGFA amplifications and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788
14. Clark GM, Zborowski DM, Santabarbara P et al (2006) Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7:389–394
15. Crinó L, Cappuzzo F, Zatloukal P et al (2008) Gefitinib versus vinorelbine in chemotherapynaive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26:4253–4260
16. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M (2006) Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51:89–96
17. Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91
18. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750
19. Epelbaum R, Schnaider J, Gluzman A (2007) Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO Gastrointestinal Cancer Symposium, Orlando, FL, 19–21 Jan 2007
20. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III randomized, open-label, first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874
21. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246
22. Garassino MC, Martelli O, Broggini M et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988
23. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552
24. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899
25. Huether A, Hopfner M, Sutter AP et al (2006) Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 12:5160–5167
26. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354
27. Iannitti D, Dipetrillo T, Akerman P (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575
28. Janjigian YY, Groen HJ, Horn L et al (2011) Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29(suppl) (abstr 7525)
29. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818
30. Kindler H, Niedzwiecki D, Hollis D et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and Leukemia group B (CALGB 80303). J Clin Oncol 28:3617–3622
31. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158
32. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabinerefractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792
33. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
34. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327
35. Llovet JM, Ricci S, Mazzaferro V et al, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
36. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
37. Lynch TJ Jr, Kim ES, Eaby B (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621
38. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non–small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865
39. Mok T, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
40. Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966
41. Moore MJ, Hamm J, Dancey J (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302
42. Natale RB (2004) Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Sem Oncol 31(3 Suppl 9):23–30
43. Neuhaus P, Riess H, Post S et al (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26 (abstr LBA4504)
44. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(suppl 4):S9–S15
45. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
46. Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
47. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311
48. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556–2568
49. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26(suppl) (abstr 4508)
50. Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer: a randomized trial. J Clin Oncol 22:3238–3247
51. Pérez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor inhibitors in lung cancer. Clin Lung Cancer 8(Suppl 1):S7–14
52. Philip PA, Benedetti J, Fenoglio-Preiser C (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (Pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC) SWOG S0205 study. J Clin Oncol 25(18 suppl) (LBA4509)
53. Philip PA, Mahoney MR, Allmer C (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663
54. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246
55. Schneider G, Hamacher R, Eser S et al (2008) Molecular biology of pancreatic cancer—new aspects and targets. Anticancer Res 28(3A):1541–1550
56. Saif MW, Merikas I, Tsimboukis S et al (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9:267–274
57. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232
58. Sandler AB (2006) Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 20(5 Suppl 2):35–40
59. Shapiro J, Marshall J, Karasek P (2005) G17DT+ gemcitabine (Gem) versus placebo + Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 23(16 suppl):4012
60. Shepherd FA, Pereira JR, Ciuleanu T et al, National Cancer Institute of Canada Clinical Trails Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
61. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 20:2607–2615
62. Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177–193
63. Thomas MB, Chadha R, Glover K (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067
64. Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843–850
65. Thongprasert S, Duffield E, Saijo N et al (2011) Health-related quality-of-life in a randomized first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6:1872–1880
66. Tsao M-S, Sakurada A, Cutz J-C et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144
67. Van Cutsem E, Van de Velde H, Karasek P (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438
68. Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. ASCO gastrointestinal cancers symposium, p A117
69. Villanueva A, Newell P, Chiang D (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76
70. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921
71. Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29(suppl 14):31–37
72. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomizsed phase 3 trial. Lancet Oncol 12:735–742
73. Zhu C-Q, da Cunha Santos G, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:4268–4275